Business Description
NervGen Pharma Corp
NAICS : 325410
SIC : 3741
ISIN : CA64082X2032
Share Class Description:
NGEN: Ordinary SharesTotal Employee Number:
9Description
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2759.75 | |||||
Equity-to-Asset | 0.15 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 2.3 | |||||
3-Year FCF Growth Rate | 6.4 | |||||
3-Year Book Growth Rate | -42.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.29 | |||||
9-Day RSI | 35.03 | |||||
14-Day RSI | 36.05 | |||||
3-1 Month Momentum % | -56.46 | |||||
6-1 Month Momentum % | -69.51 | |||||
12-1 Month Momentum % | -29.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.16 | |||||
Quick Ratio | 1.16 | |||||
Cash Ratio | 1.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.5 | |||||
Shareholder Yield % | -3.72 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -5839.38 | |||||
ROA % | -236.32 | |||||
ROIC % | -196.37 | |||||
3-Year ROIIC % | -22.08 | |||||
ROCE % | -3699.33 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 186 | |||||
Price-to-Tangible-Book | 186 | |||||
EV-to-EBIT | -9.44 | |||||
EV-to-EBITDA | -9.45 | |||||
EV-to-FCF | -13 | |||||
| Price-to-Net-Current-Asset-Value | 186 | |||||
| Price-to-Net-Cash | 186 | |||||
Earnings Yield (Greenblatt) % | -10.59 | |||||
FCF Yield % | -7.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NGEN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NervGen Pharma Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.472 | ||
| Beta | 0.4469 | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 1.05 | ||
| Volatility % | 99.67 | ||
| 14-Day RSI | 36.05 | ||
| 14-Day ATR ($) | 0.1704 | ||
| 20-Day SMA ($) | 1.9885 | ||
| 12-1 Month Momentum % | -29.46 | ||
| 52-Week Range ($) | 1.7 - 6.3 | ||
| Shares Outstanding (Mil) | 106.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NervGen Pharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NervGen Pharma Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
NervGen Pharma Corp Frequently Asked Questions
What is NervGen Pharma Corp(NGEN)'s stock price today?
The current price of NGEN is $1.86. The 52 week high of NGEN is $6.30 and 52 week low is $1.70.
When is next earnings date of NervGen Pharma Corp(NGEN)?
The next earnings date of NervGen Pharma Corp(NGEN) is .
Does NervGen Pharma Corp(NGEN) pay dividends? If so, how much?
NervGen Pharma Corp(NGEN) does not pay dividend.
Guru Commentaries on NAS:NGEN
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| NervGen Pharma To Webcast At VirtualInvestorConferences.com July 11th | 2019-07-09 |
Articles on NervGen Pharma Corp
Headlines
See More- 1
Jun 11, 2026
NervGen rises as TD Cowen issues new Buy on lead asset
Seeking Alpha • 12:45pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers